Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 66.7%Moderate 1 · 33.3%High 0 · 0%

pain ‐ 100mm VAS mm. Scale from: 0 to 100. · patients with pain management in rheumatoid arthritis

1 finding from 1 review

Neuromodulators for pain management in rheumatoid arthritis 2012 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 48 participants
Low

Withdrawals due to adverse events · patients with pain management in rheumatoid arthritis

Nefopam 60 mg tds showed no clear difference in withdrawal Due to adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Neuromodulators for pain management in rheumatoid arthritis 2012 · Cochrane Headline outcomes only
RR 11 [0.64, 189.65]
1 study · 54 participants
Moderate

Total adverse events · patients with pain management in rheumatoid arthritis

Nefopam 60 mg tds may leads to higher total adverse events compared with placebo (low certainty).

1 finding from 1 review

Neuromodulators for pain management in rheumatoid arthritis 2012 · Cochrane Headline outcomes only
RR 4.11 [1.58, 10.69]
2 studies · 104 participants
Low